CD19 and diffuse large B-cell lymphoma: The anti-PD1 antibody pembrolizumab was evaluated as a single agent in a limited number of patients with r/r DLBCL following progression after treatment with anti-CD19 CAR T-cell therapy, yielding an ORR of 25% [43].